Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 149
- Registration Number
- NCT02260648
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
A Study of LY2835219 in Healthy Participants
- First Posted Date
- 2014-10-03
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT02256267
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
A Study of Duloxetine (LY248686) in Participants With Chronic Osteoarthritis and Knee Pain in Japan
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 354
- Registration Number
- NCT02248480
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2014-09-23
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 493
- Registration Number
- NCT02246621
- Locations
- 🇦🇹
Universitaetsklinikum Allgemeines Krankenhaus Wien, Vienna, Wien, Austria
🇯🇵Shizuoka Cancer Center, Nagaizumi, Shizuoka, Japan
🇺🇸Ironwood Cancer & Research Centers, Chandler, Arizona, United States
A Study of LY3079514 in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: LY3079514Drug: Placebo
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2018-10-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT02242903
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
A Study of How the Body Breaks Down and Eliminates LY2623091
- Conditions
- Healthy Volunteers
- Interventions
- Drug: LY2623091
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6
- Registration Number
- NCT02242981
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States
A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
- First Posted Date
- 2014-09-15
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 9
- Registration Number
- NCT02240433
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suita-shi, Japan
Food-Effect Study in Healthy Participants
- First Posted Date
- 2014-09-08
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT02233296
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
- Conditions
- Hyperlipidemia
- Interventions
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 366
- Registration Number
- NCT02227784
- Locations
- 🇺🇸
Alan Graff, MD, PA, Fort Lauderdale, Florida, United States
🇺🇸Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States
🇺🇸Maryland Cardiovascular Specialists, Baltimore, Maryland, United States
A Study of Evacetrapib in Healthy Japanese Participants
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT02226653
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan